David Goldstein

Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification.

Optimising clinical practice in cancer genetics with cultural competence: lessons to be learned from ethnographic research with Chinese-Australians.

Modern management of pancreatic carcinoma.

Understanding community beliefs of Chinese-Australians about cancer: initial insights using an ethnographic approach.

Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.

Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines.

Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.

Phase II study of vinflunine in patients with metastatic renal cell carcinoma.

Primary pancreatic lymphoma--pancreatic tumours that are potentially curable without resection, a retrospective review of four cases.

Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study.

Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha.

Pancreatic stellate cells: partners in crime with pancreatic cancer cells.

Enhancing psychosocial care for people with cancer in rural communities: what can remote counselling offer?

Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance.

Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.

Role of pancreatic stellate cells in pancreatic cancer metastasis.

Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility.

Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity.

If I am in the mood, I enjoy it: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer.

Impact of oxaliplatin-induced neuropathy: a patient perspective.

New molecular and immunotherapeutic approaches in biliary cancer.

Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study.

The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.

STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review).

Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers.

Uncovering a key to the process of metastasis in human cancers: a review of critical regulators of anoikis.

The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates.

Clinical and molecular characterization of HER2 amplified-pancreatic cancer.

Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer.

Chemotherapy-induced peripheral neurotoxicity: a critical analysis.

Role of pancreatic stellate cells in chemoresistance in pancreatic cancer.

The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer.

Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations.

Impact of STAT3 inhibition on survival of osteosarcoma cell lines.

βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer.

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

The Potential of panHER Inhibition in Cancer.

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.

Migrant health in cancer: outcome disparities and the determinant role of migrant-specific variables.

Targeted therapy in soft tissue sarcoma-a novel direction in therapeutics.

"I might not have cancer if you didn't mention it": a qualitative study on information needed by culturally diverse cancer survivors.

A tsunami of unmet needs: pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health services.

Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial.

Response.

Key role of pancreatic stellate cells in pancreatic cancer.

Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?

Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.

Using a Delphi process to determine optimal care for patients with pancreatic cancer.

Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma.

Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study.

Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures.

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

Erratum to: Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study.

Determinants of Outcomes Following Resection for Pancreatic Cancer-a Population-Based Study.

Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus.

Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review.

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.

Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines.

Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review.

MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity.

Communicating with patients from minority backgrounds: Individual challenges experienced by oncology health professionals.

Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy.

Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy.

Anxiety, depression and quality of life in people with pancreatic cancer and their carers.

Communication challenges experienced by migrants with cancer: A comparison of migrant and English-speaking Australian-born cancer patients.

The role of chemotherapy in gastric cancer-related microangiopathic haemolytic anaemia.

Circulating pancreatic stellate (stromal) cells in pancreatic cancer-a fertile area for novel research.

Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.

Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue.

Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer.

Significance of Phosphorylated Epidermal Growth Factor Receptor and Its Signal Transducers in Human Soft Tissue Sarcoma.

Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey.

Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy.

Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice.

Evaluating the Impact of Functional Genetic Variation on HIV-1 Control.

Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer.

Predictors of care for patients with cancer of unknown primary site in three Australian hospitals.

Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated?

Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survival.

Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines.

A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy.

Evaluation of an online communication skills training programme for oncology nurses working with patients from minority backgrounds.

Dorsal root ganglion explants derived from chemotherapy-treated mice have reduced neurite outgrowth in culture.

Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review.

Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy.

Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.

Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test.

Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients.

Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy.

Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments.

The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy.

Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review.

Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT).

Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials.

Impact of migrancy on cancer clinical trial participation: Factors associated with approach and consent in Australian-born versus migrant groups.

The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas.

Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis.

The impact of anticancer drugs on the ocular surface.

Assessment of the Value of Tumor Variation Profiling Perceived by Patients With Cancer.

Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.

Stage pN3a in oral cancer: A redundant entity?

Acute changes in nerve excitability following oxaliplatin treatment in mice.

Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer.

Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy-a randomised controlled trial.

Self-reported health, lifestyle and social circumstances of Australian adult cancer survivors: A propensity score weighted cross-sectional study.

Oxaliplatin-induced haematological toxicity and splenomegaly in mice.